Sun Pharma Ilumetri now included in category B of China National Reimbursement Drug List
ILUMETRI is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Mumbai: Through a recent BSE filing, Sun Pharma has informed that the Company's specialty product ILUMETRI, (Tildrakizumab Injection) has been included in category B of China’s National Reimbursement Drug List.
The inclusion of Ilumetri in the list will be officially implemented from January 1, 2024.
ILUMETRI is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
In June 2019, Sun Pharma had out-licensed Tildrakizumab to a subsidiary of China Medical System Holdings Limited (CMS), for the Greater China market. ILUMETRI was approved for marketing in China in May 2023. The inclusion of ILUMETRI in category B of the National Reimbursement Drug List will further improve the accessibility and affordability of the innovative drug to benefit more patients.
Read also: Sun Pharma arm signs licensing agreement with Aclaris Therapeutics
Read also: Sun Pharma, WOTR to create over 5.2 billion litres of water harvesting capacity in rural Maharashtra
